Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection)

Important Risk Information

Ovidrel® PreFilled Syringe is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) and ovarian enlargement with or without pulmonary and vascular complications.

Adverse reactions reported include injection site reactions, GI disorders, abdominal pain, nausea, vomiting, ovarian cyst, ovarian hyperstimulation, and thromboembolic events. Multiple births and congenital abnormalities have been reported.

For complete information, please see full Prescribing information.

Ovidrel® is a registered trademark of Merck KGaA, Darmstadt, Germany or its affiliates.